In relation to the previous post, one mustn't forget there is competition out there as well. There is no guarantee that even if you get your drug to market that it will become the dominant player. Fierce Biotech reports this morning that Merck's boceprevir hit all its primary endpoints in its two latest phase III trials.
So now it will be a bit of a race between boceprevir and telaprevir for dominance in the hepatitis C treatment market. Telaprevir has also performed very well in its clinical trials and may have fewer side effects (like anemia) than boceprevir.
Nevertheless, the market will decide which drug prevails.
Posted by Bruce Lehr August 4th 2010.